Abstract

Effect of PCSK9 inhibition with evolocumab on the concentration and composition of LDL subfractions in high-risk patients with cardiovascular disease

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call